Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-19-095
Prinicipal Investigator
Ma, Patrick
Phase
Phase III
Age Group
Adult
Scope
National
Secondary Protocol No.
MK 3475-867-01 KEYNOTE-867
Title
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)(KEYNOTE-867) MK 3475-867
Objective
- To compare the Event Free Survival (EFS).
- Hypothesis: SBRT + pembrolizumab prolongs EFS compared to SBRT + placebo.
- To compare Overall Survival (OS).
- Hypothesis: SBRT + pembrolizumab prolongs OS compared to SBRT + placebo.
Applicable Disease Sites
Lung
Status
Open
Participating Institutions
Hershey Medical Center